Based on its promising results, a multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer (HERB trial) is ongoing in Japan [40]. The gene discussed is ERBB2; the disease is biliary tract cancer.